Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedSite revision label updated from v3.4.2 to v3.4.3 in the page header/footer.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision: v3.4.2 was applied, replacing the previous v3.4.1. No substantive study information or user-facing content was changed.SummaryDifference0.1%

- Check55 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1, which does not alter the study details, inclusion criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check69 days agoChange DetectedMinor UI/text updates: Show glossary and Hide glossary controls were added, along with a new 'Last Update Submitted that Met QC Criteria' label and a Revision: v3.4.0 tag. Wording and capitalization tweaks were made to 'No FEAR Act Data' and 'Last Update Submitted that met QC Criteria'.SummaryDifference0.3%

- Check76 days agoChange DetectedRevision: v3.3.4 was added and the previous Revision: v3.3.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.